UK small-cap RNS · 27 Jul 2026
The key announcements of UK small & mid caps under £2bn on 27 Jul 2026 – situations they move are marked, with the share price since.
Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus director dealings and holdings that are part of a situation. Not investment advice.
| Date | Company | Mcap ↕ | Type | Announcement | |
|---|---|---|---|---|---|
| 27 Jul | Pathos Communications plc NEWS | £19m | Upgrade / downgrade cycle | H1 2026 Trading Update
Double digit growth in Revenue and Adjusted EBITDA; |
|
| 27 Jul | CVS Group CVSG | £884m | Routine | Transaction in Own Shares | |
| 27 Jul | Globaldata DATA | £422m | Routine | Transaction in Own Shares | |
| 27 Jul | Big Technologies BIG | £268m | Trading Update and Notice of Results
("Big Technologies" or "the Company" and, together with its subsidiaries, the "Group") |
||
| 27 Jul | Macfarlane Group MACF | £124m | Routine | Transaction in Own Shares | |
| 27 Jul | Science Group SAG | £229m | Capital return | Half-year Results
· Resilient H1 performance positions Group for another solid year |
|
| 27 Jul | M&C Saatchi SAA | £137m | Routine | Transaction in Own Shares | |
| 27 Jul | Mcbride MCB | £299m | Routine | Transaction in Own Shares | |
| 27 Jul | Permanent TSB Group Holdings (CDI) PTSB | £1,370m | Routine | Form 8.3 - Permanent TSB Group Holdings plc | |
| 27 Jul | Faron Pharmaceuticals Oy FARN | £66m | Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial
Inside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients. |
||
| 27 Jul | OSB Group OSB | £1,615m | Routine | OSB GROUP PLC - Transaction in Own Shares |